| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone ... The Lancet 368 (9541), 1096-1105, 2006 | 2268 | 2006 |
| Osteoporosis in lung transplantation candidates with end-stage pulmonary disease E Shane, SJ Silverberg, D Donovan, A Papadopoulos, RB Staron, ... The American journal of medicine 101 (3), 262-269, 1996 | 335 | 1996 |
| Vitamin D and calcium dysregulation in the polycystic ovarian syndrome S Thys-Jacobs, D Donovan, A Papadopoulos, P Sarrel, JP Bilezikian Steroids 64 (6), 430-435, 1999 | 315 | 1999 |
| Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus K Nagashima, C Lopez, D Donovan, C Ngai, N Fontanez, A Bensadoun, ... The Journal of clinical investigation 115 (5), 1323-1332, 2005 | 231 | 2005 |
| Effect of sodium intake on insulin sensitivity DS Donovan, CG Solomon, EW Seely, GH Williams, DC Simonson American Journal of Physiology-Endocrinology and Metabolism 264 (5), E730-E734, 1993 | 194 | 1993 |
| BONE LOSS AND FRACTURE AFTER LUNG TRANSPLANTATION1 E Shane, A Papadopoulos, RB Staron, V Addesso, D Donovan, ... Transplantation 68 (2), 220-227, 1999 | 145 | 1999 |
| Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects JS Millar, G Reyes-Soffer, P Jumes, RL Dunbar, EM deGoma, AL Baer, ... The Journal of clinical investigation 125 (6), 2510-2522, 2015 | 86 | 2015 |
| Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein AI and plasma cholesteryl ester … G Reyes-Soffer, JS Millar, C Ngai, P Jumes, E Coromilas, B Asztalos, ... Arteriosclerosis, thrombosis, and vascular biology 36 (5), 994-1002, 2016 | 41 | 2016 |
| 1 Aetiology and pathogenesis of hormonal and metabolic disorders in HIV infection SK Grinspoon, DS Donovan Jr, JP Bilezikian Baillière's clinical endocrinology and metabolism 8 (4), 735-755, 1994 | 40 | 1994 |
| Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans G Reyes-Soffer, B Moon, A Hernandez-Ono, M Dionizovik-Dimanovski, ... Science translational medicine 8 (323), 323ra12-323ra12, 2016 | 34 | 2016 |
| Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E [S] JS Millar, ME Lassman, T Thomas, R Ramakrishnan, P Jumes, ... Journal of lipid research 58 (6), 1214-1220, 2017 | 24 | 2017 |
| Epidemiology of diabetes and its burden in the World and in the United States. Principles of Diabetes Mellitus. Ed: L Poretsky DS Donovan Boston, Dordrecht, London, Kluwer Academic Publishers, 2002 | 24 | 2002 |
| Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo … MJ Glesby, J Albu, YL Chiu, K Ham, E Engelson, Q He, V Muthukrishnan, ... PLoS One 8 (4), e61160, 2013 | 15 | 2013 |
| Status of endocrine disease with HIV infection DS Donovan Jr, RG Dluhy Current therapy in endocrinology and metabolism 5, 190-194, 1994 | 13 | 1994 |
| Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects JS Millar, G Reyes-Soffer, P Jumes, RL Dunbar, EM deGoma, AL Baer, ... The Journal of Clinical Investigation 126 (4), 1603-1604, 2016 | 11 | 2016 |
| Effect of recombinant human growth hormone and rosiglitazone for HIV-associated abdominal fat accumulation on adiponectin and other markers of inflammation V Leung, YL Chiu, DP Kotler, J Albu, YS Zhu, K Ham, ES Engelson, ... HIV clinical trials 17 (2), 55-62, 2016 | 9 | 2016 |
| Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus MR Rubin, AB Goldfine, DJ McMahon, DS Donovan, S Cremers, ... Endocrine 50, 504-507, 2015 | 7 | 2015 |
| Effect of metformin/glyburide tablets on postprandial insulin as first-line in type 2 diabetes J ROSENSTOCK, D DONOVAN, BA PIPER Diabetes 49 (5), A364-A364, 2000 | 4 | 2000 |
| Effects of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid and lipoprotein metabolism in healthy subjects G Reyes-Soffer, M Pavlyha, C Ngai, T Thomas, S Holleran, ... Circulation 132 (suppl_3), A18390-A18390, 2015 | 3 | 2015 |
| Effect of metformin/glyburide tablets on fasting plasma glucose in type 2 diabetes D DONOVAN, J ROSENTOCK, A MOORADIAN, D HENRY Diabetes 49 (5), A103-A103, 2000 | 3 | 2000 |
